



Clinical trial results: Prospective Multi-Center Evaluation of the Duration of Therapy for Thrombosis in Children Summary

| | |
|--------------------------|------------------|
| EudraCT number | 2015-001776-21 |
| Trial protocol | AT NL |
| Global end of trial date | 31 December 2021 |

Results information

| | |
|--------------------------------|-----------------|
| Result version number | v1 (current) |
| This version publication date | 08 October 2023 |
| First version publication date | 08 October 2023 |

Trial information

Trial identification

| | |
|-----------------------|-------------|
| Sponsor protocol code | NCT00687882 |
|-----------------------|-------------|

Additional study identifiers

| | |
|------------------------------------|---------------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT00687882 |
| WHO universal trial number (UTN) | - |
| Other trial identifiers | Kids-DOTT: KidsDOTT |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | Medizinische Universität Wien |
| Sponsor organisation address | Spitalgasse 23, Wien, Austria, 1090 |
| Public contact | Univ. Prof. Dr. , M.Sc Christoph Male, Medizinische Universität Wien, Universitätsklinik für Kinder- und Jugendheilkunde, 0043 14040021100, christoph.male@meduniwien.ac.at |
| Scientific contact | Univ. Prof. Dr. , M.Sc Christoph Male, Medizinische Universität Wien, Universitätsklinik für Kinder- und Jugendheilkunde, 0043 14040021100, christoph.male@meduniwien.ac.at |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 01 April 2021 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 31 January 2021 |
| Global end of trial reached? | Yes |
| Global end of trial date | 31 December 2021 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

To evaluate the efficacy and safety of shortened-duration (6 weeks total) versus conventional-duration (3 months total) anticoagulation for first-episode, provoked, acute venous thrombosis among children in whom thrombus resolution/non-occlusion (i.e. established blood flow) is evident after the initial 6 weeks of anticoagulant therapy

Hypothesis: Among children with first-episode, provoked, acute venous thrombosis in whom thrombosis is resolved or non-occlusive at six weeks follow-up, a shortened duration of anticoagulation (total six weeks; i.e. no further therapy) is non-inferior in efficacy to the conventional duration (total three months) of anticoagulation with respect to the risk of symptomatic recurrent VTE at 1 year, and is superior in safety with respect to the risk of clinically-relevant bleeding. (The hypothesis will also be tested in secondary analysis at 2 years, using the same efficacy and safety outcomes as for the 1 year primary analysis.)

Protection of trial subjects:

yes

Background therapy: -

Evidence for comparator: -

| | |
|---|------------------|
| Actual start date of recruitment | 30 November 2008 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|------------|
| Country: Number of subjects enrolled | Austria: 6 |
| Worldwide total number of subjects | 6 |
| EEA total number of subjects | 6 |

Notes:

Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 1 |
| Children (2-11 years) | 2 |
| Adolescents (12-17 years) | 3 |

| | |
|----------------------|---|
| Adults (18-64 years) | 0 |
| From 65 to 84 years | 0 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

Children (birth to < 21a) with acute deep venous thrombosis in the past 30 days

Pre-assignment

Screening details:

children with provoked event (central venous line, infection, dehydration, surgery, trauma...)

Period 1

| | |
|------------------------------|---------------------------|
| Period 1 title | baseline (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Not blinded |

Arms

| | |
|------------------|-----------------------------------|
| Arm title | Duration of anticoagulant therapy |
|------------------|-----------------------------------|

Arm description:

duration (6 or 12 weeks total)

| | |
|--|-------------------|
| Arm type | Active comparator |
| Investigational medicinal product name | Marcoumar |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Coated tablet |
| Routes of administration | Oral use |

Dosage and administration details:

depending on patients INR value

| | |
|--|------------------------|
| Investigational medicinal product name | Lovenox |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

depending on patients anti Xa value

| Number of subjects in period 1 | Duration of anticoagulant therapy |
|--------------------------------|-----------------------------------|
| Started | 6 |
| Completed | 5 |
| Not completed | 1 |
| Adverse event, serious fatal | 1 |

Baseline characteristics

Reporting groups

| | |
|-----------------------|-----------------------------------|
| Reporting group title | Duration of anticoagulant therapy |
|-----------------------|-----------------------------------|

| |
|--|
| Reporting group description: duration (6 or 12 weeks total) |
|--|

| Reporting group values | Duration of anticoagulant therapy | Total | |
|--|-----------------------------------|-------|--|
| Number of subjects | 6 | 6 | |
| Age categorical Units: Subjects | | | |
| In utero | 0 | 0 | |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | |
| Newborns (0-27 days) | 1 | 1 | |
| Infants and toddlers (28 days-23 months) | 2 | 2 | |
| Children (2-11 years) | 0 | 0 | |
| Adolescents (12-17 years) | 3 | 3 | |
| Adults (18-64 years) | 0 | 0 | |
| From 65-84 years | 0 | 0 | |
| 85 years and over | 0 | 0 | |
| Gender categorical Units: Subjects | | | |
| Female | 2 | 2 | |
| Male | 4 | 4 | |

Subject analysis sets

| | |
|----------------------------|-----------|
| Subject analysis set title | Marcoumar |
|----------------------------|-----------|

| | |
|---------------------------|--------------------|
| Subject analysis set type | Intention-to-treat |
|---------------------------|--------------------|

| |
|-----------------------------------|
| Subject analysis set description: |
|-----------------------------------|

| |
|---|
| 6 weeks duration of anticoagulant therapy |
|---|

| | |
|----------------------------|-----------|
| Subject analysis set title | Marcoumar |
|----------------------------|-----------|

| | |
|---------------------------|--------------------|
| Subject analysis set type | Intention-to-treat |
|---------------------------|--------------------|

| |
|-----------------------------------|
| Subject analysis set description: |
|-----------------------------------|

| |
|--|
| 12 weeks duration of anticoagulant therapy |
|--|

| | |
|----------------------------|---------|
| Subject analysis set title | Lovenox |
|----------------------------|---------|

| | |
|---------------------------|--------------------|
| Subject analysis set type | Intention-to-treat |
|---------------------------|--------------------|

| |
|-----------------------------------|
| Subject analysis set description: |
|-----------------------------------|

| |
|---|
| duration of anticoagulant therapy 6 weeks |
|---|

| Reporting group values | Marcoumar | Marcoumar | Lovenox |
|------------------------------------|-----------|-----------|---------|
| Number of subjects | 5 | 3 | 1 |
| Age categorical Units: Subjects | | | |
| In utero | 0 | 0 | 0 |

| | | | |
|---|---|---|---|
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 1 |
| Infants and toddlers (28 days-23 months) | 2 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 3 | 3 | 0 |
| Adults (18-64 years) | 0 | 0 | 0 |
| From 65-84 years | 0 | 0 | 0 |
| 85 years and over | 0 | 0 | 0 |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 2 | 2 | 0 |
| Male | 3 | 1 | 1 |

End points

End points reporting groups

| | |
|---|-----------------------------------|
| Reporting group title | Duration of anticoagulant therapy |
| Reporting group description: duration (6 or 12 weeks total) | |
| Subject analysis set title | Marcoumar |
| Subject analysis set type | Intention-to-treat |
| Subject analysis set description: 6 weeks duration of anticoagulant therapy | |
| Subject analysis set title | Marcoumar |
| Subject analysis set type | Intention-to-treat |
| Subject analysis set description: 12 weeks duration of anticoagulant therapy | |
| Subject analysis set title | Lovenox |
| Subject analysis set type | Intention-to-treat |
| Subject analysis set description: duration of anticoagulant therapy 6 weeks | |

Primary: Occurrence of symptomatic recurrent VTE within 1 year

| | |
|--------------------------------|--|
| End point title | Occurrence of symptomatic recurrent VTE within 1 year ^[1] |
| End point description: | |
| End point type | Primary |
| End point timeframe: 1 year | |

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: statistical analyses were performed at John Hopkins All children`s Hospital (St. Petersburg, FL, USA)

| End point values | Marcoumar | Marcoumar | Lovenox | |
|-----------------------------|----------------------|----------------------|----------------------|--|
| Subject group type | Subject analysis set | Subject analysis set | Subject analysis set | |
| Number of subjects analysed | 5 | 3 | 1 | |
| Units: thrombotic events | 0 | 0 | 0 | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information^[1]

Timeframe for reporting adverse events:

until follow up visit after 1 year

| | |
|-----------------|----------------|
| Assessment type | Non-systematic |
|-----------------|----------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 24.1 |
|--------------------|------|

Frequency threshold for reporting non-serious adverse events: 0 %

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: No AEs occurred in relation with medication

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|--------------|--|
| 11 July 2019 | changes to protocol, ICF, screening log, Manual of Operations and recruitment brochure |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported